Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol

Bernard W. Parker, Gurmeet Kaur, Wilberto Nieves-Neira, Mohammed Taimi, Glenda Kohlhagen, Tsunehiro Shimizu, Michael D. Losiewicz, Yves Pommier, Edward A. Sausville, Adrian M. Senderowicz

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Flavopiridol (NSC 649890; Behringwerke L86-8275, Marburg, Germany), is a potent inhibitor of cyclin dependent kinases (CDKs) 1, 2, and 4. It has potent antiproliferative effects in vitro and is active in tumor models in vivo. While surveying the effect of flavopiridol on cell cycle progression in different cell types, we discovered that hematopoietic cell lines, including SUDHL4, SUDHL6 (B-cell lines), Jurkat, and MOLT4 (T-cell lines), and HL60 (myeloid), displayed notable sensitivity to flavopiridol-induced apoptosis. For example, after 100 nmol/L for 12 hours, SUDHL4 cells displayed a similar degree of DNA fragmentation to that shown by the apoptosis-resistant PC3 prostate carcinoma cells only after 3,000 nmol/L for 48 hours. After eXPOSure to 1,000 nmol/L flavopiridol for 12 hours, typical apoptotic morphology was observed in SUDHL4 cells, but not in PC3 prostate carcinoma cells despite comparable potency (SUDHL4:120 nmol/L; PC3:203 nmol/L) in causing growth inhibition by 50% (IC50). Flavopiridol did not induce topoisomerase I or II cleavable complex activity. A relation of p53, bcl2, or bax protein levels to apoptosis in SUDHL4 was not appreciated. While flavopiridol caused cell cycle arrest with decline in CDK1 activity in PC3 cells, apoptosis of SUDHL4 cells occurred without evidence of cell cycle arrest. These results suggest that antiproliferative activity of flavopiridol (manifest by cell cycle arrest) may be separated in different cell types from a capacity to induce apoptosis. Cells from hematopoietic neoplasma appear in this limited sample to be very susceptible to flavopiridol-induced apoptosis and therefore clinical trials in hematopoietic neoplasms should be of high priority.

Original languageEnglish (US)
Pages (from-to)458-465
Number of pages8
JournalBlood
Volume91
Issue number2
StatePublished - Jan 15 1998
Externally publishedYes

Fingerprint

alvocidib
Cells
Apoptosis
Cell Line
Cell Cycle Checkpoints
Prostate
CDC2 Protein Kinase
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 2
Carcinoma
bcl-2-Associated X Protein
Type II DNA Topoisomerase
Type I DNA Topoisomerase
T-cells
Surveying
DNA Fragmentation
Hematologic Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Parker, B. W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., ... Senderowicz, A. M. (1998). Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91(2), 458-465.

Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. / Parker, Bernard W.; Kaur, Gurmeet; Nieves-Neira, Wilberto; Taimi, Mohammed; Kohlhagen, Glenda; Shimizu, Tsunehiro; Losiewicz, Michael D.; Pommier, Yves; Sausville, Edward A.; Senderowicz, Adrian M.

In: Blood, Vol. 91, No. 2, 15.01.1998, p. 458-465.

Research output: Contribution to journalArticle

Parker, BW, Kaur, G, Nieves-Neira, W, Taimi, M, Kohlhagen, G, Shimizu, T, Losiewicz, MD, Pommier, Y, Sausville, EA & Senderowicz, AM 1998, 'Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol', Blood, vol. 91, no. 2, pp. 458-465.
Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood. 1998 Jan 15;91(2):458-465.
Parker, Bernard W. ; Kaur, Gurmeet ; Nieves-Neira, Wilberto ; Taimi, Mohammed ; Kohlhagen, Glenda ; Shimizu, Tsunehiro ; Losiewicz, Michael D. ; Pommier, Yves ; Sausville, Edward A. ; Senderowicz, Adrian M. / Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. In: Blood. 1998 ; Vol. 91, No. 2. pp. 458-465.
@article{77b86a0393f44d5989ae5b76eb8a38c9,
title = "Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol",
abstract = "Flavopiridol (NSC 649890; Behringwerke L86-8275, Marburg, Germany), is a potent inhibitor of cyclin dependent kinases (CDKs) 1, 2, and 4. It has potent antiproliferative effects in vitro and is active in tumor models in vivo. While surveying the effect of flavopiridol on cell cycle progression in different cell types, we discovered that hematopoietic cell lines, including SUDHL4, SUDHL6 (B-cell lines), Jurkat, and MOLT4 (T-cell lines), and HL60 (myeloid), displayed notable sensitivity to flavopiridol-induced apoptosis. For example, after 100 nmol/L for 12 hours, SUDHL4 cells displayed a similar degree of DNA fragmentation to that shown by the apoptosis-resistant PC3 prostate carcinoma cells only after 3,000 nmol/L for 48 hours. After eXPOSure to 1,000 nmol/L flavopiridol for 12 hours, typical apoptotic morphology was observed in SUDHL4 cells, but not in PC3 prostate carcinoma cells despite comparable potency (SUDHL4:120 nmol/L; PC3:203 nmol/L) in causing growth inhibition by 50{\%} (IC50). Flavopiridol did not induce topoisomerase I or II cleavable complex activity. A relation of p53, bcl2, or bax protein levels to apoptosis in SUDHL4 was not appreciated. While flavopiridol caused cell cycle arrest with decline in CDK1 activity in PC3 cells, apoptosis of SUDHL4 cells occurred without evidence of cell cycle arrest. These results suggest that antiproliferative activity of flavopiridol (manifest by cell cycle arrest) may be separated in different cell types from a capacity to induce apoptosis. Cells from hematopoietic neoplasma appear in this limited sample to be very susceptible to flavopiridol-induced apoptosis and therefore clinical trials in hematopoietic neoplasms should be of high priority.",
author = "Parker, {Bernard W.} and Gurmeet Kaur and Wilberto Nieves-Neira and Mohammed Taimi and Glenda Kohlhagen and Tsunehiro Shimizu and Losiewicz, {Michael D.} and Yves Pommier and Sausville, {Edward A.} and Senderowicz, {Adrian M.}",
year = "1998",
month = "1",
day = "15",
language = "English (US)",
volume = "91",
pages = "458--465",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol

AU - Parker, Bernard W.

AU - Kaur, Gurmeet

AU - Nieves-Neira, Wilberto

AU - Taimi, Mohammed

AU - Kohlhagen, Glenda

AU - Shimizu, Tsunehiro

AU - Losiewicz, Michael D.

AU - Pommier, Yves

AU - Sausville, Edward A.

AU - Senderowicz, Adrian M.

PY - 1998/1/15

Y1 - 1998/1/15

N2 - Flavopiridol (NSC 649890; Behringwerke L86-8275, Marburg, Germany), is a potent inhibitor of cyclin dependent kinases (CDKs) 1, 2, and 4. It has potent antiproliferative effects in vitro and is active in tumor models in vivo. While surveying the effect of flavopiridol on cell cycle progression in different cell types, we discovered that hematopoietic cell lines, including SUDHL4, SUDHL6 (B-cell lines), Jurkat, and MOLT4 (T-cell lines), and HL60 (myeloid), displayed notable sensitivity to flavopiridol-induced apoptosis. For example, after 100 nmol/L for 12 hours, SUDHL4 cells displayed a similar degree of DNA fragmentation to that shown by the apoptosis-resistant PC3 prostate carcinoma cells only after 3,000 nmol/L for 48 hours. After eXPOSure to 1,000 nmol/L flavopiridol for 12 hours, typical apoptotic morphology was observed in SUDHL4 cells, but not in PC3 prostate carcinoma cells despite comparable potency (SUDHL4:120 nmol/L; PC3:203 nmol/L) in causing growth inhibition by 50% (IC50). Flavopiridol did not induce topoisomerase I or II cleavable complex activity. A relation of p53, bcl2, or bax protein levels to apoptosis in SUDHL4 was not appreciated. While flavopiridol caused cell cycle arrest with decline in CDK1 activity in PC3 cells, apoptosis of SUDHL4 cells occurred without evidence of cell cycle arrest. These results suggest that antiproliferative activity of flavopiridol (manifest by cell cycle arrest) may be separated in different cell types from a capacity to induce apoptosis. Cells from hematopoietic neoplasma appear in this limited sample to be very susceptible to flavopiridol-induced apoptosis and therefore clinical trials in hematopoietic neoplasms should be of high priority.

AB - Flavopiridol (NSC 649890; Behringwerke L86-8275, Marburg, Germany), is a potent inhibitor of cyclin dependent kinases (CDKs) 1, 2, and 4. It has potent antiproliferative effects in vitro and is active in tumor models in vivo. While surveying the effect of flavopiridol on cell cycle progression in different cell types, we discovered that hematopoietic cell lines, including SUDHL4, SUDHL6 (B-cell lines), Jurkat, and MOLT4 (T-cell lines), and HL60 (myeloid), displayed notable sensitivity to flavopiridol-induced apoptosis. For example, after 100 nmol/L for 12 hours, SUDHL4 cells displayed a similar degree of DNA fragmentation to that shown by the apoptosis-resistant PC3 prostate carcinoma cells only after 3,000 nmol/L for 48 hours. After eXPOSure to 1,000 nmol/L flavopiridol for 12 hours, typical apoptotic morphology was observed in SUDHL4 cells, but not in PC3 prostate carcinoma cells despite comparable potency (SUDHL4:120 nmol/L; PC3:203 nmol/L) in causing growth inhibition by 50% (IC50). Flavopiridol did not induce topoisomerase I or II cleavable complex activity. A relation of p53, bcl2, or bax protein levels to apoptosis in SUDHL4 was not appreciated. While flavopiridol caused cell cycle arrest with decline in CDK1 activity in PC3 cells, apoptosis of SUDHL4 cells occurred without evidence of cell cycle arrest. These results suggest that antiproliferative activity of flavopiridol (manifest by cell cycle arrest) may be separated in different cell types from a capacity to induce apoptosis. Cells from hematopoietic neoplasma appear in this limited sample to be very susceptible to flavopiridol-induced apoptosis and therefore clinical trials in hematopoietic neoplasms should be of high priority.

UR - http://www.scopus.com/inward/record.url?scp=0031963058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031963058&partnerID=8YFLogxK

M3 - Article

C2 - 9427698

AN - SCOPUS:0031963058

VL - 91

SP - 458

EP - 465

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -